Search Results

Raimond Heukers , developed a nanobody platform within the research group and used this platform to develop He currently is focusing on the development of nanobody-based immuno tracers as part of the IMI/EFPIA

Sampedro-Castaneda, Marisol1, Claxton, Suzanne1, Skehel, Mark2, Ultanir, Sila K.1 1Kinases and Brain Development Mihaylov " I am a postdoctoral researcher in the kinases and brain development laboratory led by Dr Sila moved to King's College London, where my interest and passion for kinases in brain health and disease developed I have recently also developed a strong interest in adhesion GPCRs and in particular, Bai1. " Simeon

Department, Ken Vecchio helping set the foundation for the Nanoengineering Materials Research Center and developing Scientists and Engineers working at the nanoscale, specifically protein engineering and small molecule drug development

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based stream is now forming the basis of a new technology-based start-up company, HeptOME , to help screen and develop

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based stream is now forming the basis of a new technology-based start-up company, HeptOME , to help screen and develop

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based stream is now forming the basis of a new technology-based start-up company, HeptOME , to help screen and develop

Pierre Eftekhari "Clinical physiologist and biologist , with more than 25 years of experience in drug development I have participated and initiated methodologies for development of pharmacologically active anti-GPCR

completed his postdoctoral training at MIT and Harvard Med School in the lab of Hidde Ploegh , where he developed Work in his independent laboratory is focused on developing new pharmacological tools via chemistry and

One example of our recent work surrounds a structure-based effort to develop ligands that specifically Our goal is to develop safer beta2AR-selective ligands for the treatment of asthma and acute rescue therapy The Sunahara lab has also been developing protein-based therapeutics using structure-guided design and Through structural and computational approaches the Sunahara lab and collaborators developed a thermostable

This was followed by a postdoctoral role at the Polytechnic University of Turin (Italy), where he developed Now in a tenure-track position, his research spans the development of computational methods such as structure-based

His research interest lies in understanding the molecular basis for human tumor development and how to Van Meir has developed novel therapeutic approaches for cancer using oncolytic adenoviruses and anti-angiogenic molecules and is currently developing novel small molecule inhibitors of the hypoxia-inducible factor His research aims to translate these novel agents to testing in clinical trials with the hope to develop the future, we plan to decipher the roles of N-glycosylation of ADGRG6 in organogenesis and tissue development

Ben’s research focuses on Smoothened and other class F GPCRs which play essential roles in embryonic development within the primary cilium, a tiny antenna-shaped structure at the cell surface with critical links to development Ben studied developmental and cancer signaling as a postdoctoral fellow with Philip Beachy at Stanford

My project involved the development of FRET/BRET -based GPCR conformational biosensors, which can be I spent 2 1/2 years in his lab and developed novel conformational sensors for these intriguing receptors

identification of small molecule regulators of these proteins, and progressing such ligands in drug development non-alcoholic steatohepatitis (NASH) and inflammatory diseases and Keltic Pharma Therapeutics (2020) which is developing

She developed expertise over the past two decades studying structure/function relationships of GPCRs the fundamental knowledge of GPCR biology and for the identification of drug targets and future drug development Manager, where they managed a technical support team providing scientific data analysis and database development contributed analytic support resulting in authorship of numerous scientific publications and new funding, and developed delivered technical presentations and software demonstrations to prospective customers worldwide, and developed

Together with Irina Kufareva , UCSD, her team developed a novel approach to identifying ligands for orphan GPCRs by developing a powerful new computational tool for identifying ‘surrogate’ ligands (borrowed

Dr Stagg has served as an expert consultant in the development of adenosine-targeting drugs, several permanent member of the Scientific Advisory Board (SAB) of Surface Oncology, a clinical stage company developing

consultancy and data analysis company supporting pharmaceutical, life science, and academic scientists in the development He specializes in kinetic analysis of drug action and is known for applying binding kinetics to the development

Mid-career, he has worked in finance and developed high-frequency trading systems. early-stage medical device start-up and in 5 years was responsible for project R&D and managing a focused development

In 2005 he started working on the development of conformational thermostabilization of GPCRs, which resulted In 2016 mini-G proteins were developed as a tool for the structure determination of GPCRs in the fully

He has focussed on developing a comprehensive map of ovarian cancer essential genes using whole genome Several of these targets are being developed for potential new therapeutic strategies in ovarian and

insightful experiences in academic, hospital, and industry labs, I decided to pursue a role in business development intersection of science and business, which includes target selection, preclinical strategy and business development to elucidate the role of steroidogenesis in regulating sexual determination and adrenal and gonadal development understand how the principles of receptor allosterism and functional selectivity can be leveraged in the development

Bridge theory to practical drug development decisions?

mispronunciations, cultural differences, and the importance of a multidisciplinary approach in drug development discussed their research interests, particularly in the field of GPCR, and the importance of method development discussed their professional backgrounds, highlighting the benefits of a multidisciplinary approach in drug development They also highlighted the importance of method development, integrity, and honesty in scientific research

and experimental systems (purified proteins, cultured cells, model organisms) in combination with the development Our ongoing efforts have direct implications in cancer, embryonic development defects, and neurological

discussed the importance of hiring based on differentiation, impact, and interest, the need for workforce development will share notes about PRISM and presentability with Arthur. - Arthur will share the story of PRISM's development Lastly, they discussed the growth and development of the Monash Institute of Pharmaceutical Sciences, significance of fundamental discoveries, the role of biotech, and the need for efficiency and process development They also discussed the disruption within the pharmaceutical sector, the importance of workforce development

discussed the importance of hiring based on differentiation, impact, and interest, the need for workforce development will share notes about PRISM and presentability with Arthur. - Arthur will share the story of PRISM's development Lastly, they discussed the growth and development of the Monash Institute of Pharmaceutical Sciences, significance of fundamental discoveries, the role of biotech, and the need for efficiency and process development They also discussed the disruption within the pharmaceutical sector, the importance of workforce development

receptor 110 (ADGRF1, GPR110), an adhesion GPCR recently deorphanized, plays an important role in in the development activation promotes neurogenic differentiation of neural stem cells, neurite growth, and synaptogenesis of developing Regulates Mating In The Closest Relatives Of Animals Alain Garcia De Las Bayonas Abstract "All animals develop

Robert Laprairie is an Associate Professor and the Saskatchewan Research Chair in Drug Discovery and Development

He has more than 20 years of experience in GPCR, primarily focused on drug discovery and developing new